BioSpace News Archive

Satsuma Pharmaceuticals, Inc . today announced completion of subject enrollment in the Company’s ongoing STS101 SUMMIT pivotal Phase 3 efficacy trial, with more than 1,400 subjects randomized. Satsuma expects to announce topline results from the SUMMIT trial in the fourth quarter of 2022.

Aprea Therapeutics, Inc. today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET.

Neuronetics, Inc. today announced its financial and operating results for the second quarter of 2022.

Avidity Biosciences, Inc. today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Disease Prevention of the Amsterdam UMC and researchers of the Danish Rigshospitalet.

Ardelyx, Inc. today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.

Mycovia Pharmaceuticals, Inc. has announced that it will present topline results from two studies evaluating VIVJOA™.

Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays.

ŌNŌCOR LLC is excited to announce the first-in-human use of the ŌNŌ endovascular retrieval system for removal of an intracardiac tumor. Intracardiac tumors affect thousands of patients around the world annually, but prior to ŌNŌ, open-heart surgery was required for removal.

Astellas Pharma Inc. announced the following changes to its management structure effective October 1, 2022.